News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.
The blood test is the lead product for the Palo Alto, California-based company, which in 2018 purchased the assets of defunct proteomics outfit Applied Proteomics.
The partners will assess Stella's assay by quantifying proto-oncogenes in Barrett's esophagus tissue that have progressed to cancer, and those that have not.
BioMark Diagnostics has been collaborating on the test with the Metabolomics Innovation Centre at the University of Alberta since early 2015.
The deal covers Agena's MassArray platform for genetic variant measurement, as well as genetic testing applications and other related products.
The test relies on a spermine risk score coupled with a urine test to predict which patients are most likely to have prostate cancer.
